市場調查報告書
商品編碼
1416204
抗體治療市場- 按類型[單株抗體(mAb) {腫瘤、自體免疫疾病、傳染病}、抗體藥物偶聯物(ADC)]、按最終用途(醫院、專科中心)分類- 全球預測,2023年- 2032 年Antibody Therapy Market - By Type [Monoclonal Antibodies (mAbs) {Oncology, Autoimmune Disease, Infectious Disease}, Antibody-drug Conjugates (ADCs)], By End-use (Hospitals, Specialty Centers) - Global Forecast, 2023 - 2032 |
預計從 2023 年到 2032 年,抗體治療市場規模將以 11.8% 的CAGR擴大。癌症和自體免疫疾病等慢性疾病的盛行率不斷上升,刺激了對多種針對性和個人化治療的需求。
生物技術和免疫學的不斷進步正在鼓勵新型且更有效的抗體療法的開發。例如,2023 年 9 月,Manaolana Oncology Inc. 透過德州大學 MD 安德森癌症中心和 Panacea Venture 之間的合作正式成立,旨在開發和推進針對新興癌症抗原的基於抗體的療法。此外,人們越來越意識到抗體療法的好處,包括減少副作用和改善治療結果,這將增加他們的需求。抗體藥物研發投入的增加以及各醫療領域應用範圍的擴大將進一步推動市場擴張。
抗體治療行業按類型、最終用途和地區分類。
預計從 2023 年到 2032 年,抗體藥物偶聯物領域的市場佔有率將以 11.6% 的CAGR成長。這主要是由於研發活動的增加、癌症患病率的上升以及生物技術的突飛猛進。對標靶和個人化治療的高需求也將推動該細分市場的成長。
預計 2023 年至 2032 年間,專科中心最終用途領域的抗體治療市場佔有率將以 12.5% 的CAGR成長。這一成長可歸因於慢性病患病率的不斷上升、尋求專業護理的患者群體的擴大以及醫療技術的不斷進步。精準醫療。此外,專科中心在提供標靶治療方面發揮著至關重要的作用,推動了抗體療法在這些中心的採用。
從地區來看,由於慢性病盛行率不斷上升以及生物製藥研發投資不斷增加,歐洲抗體治療市場規模預計從2023年到2032年將以11.6%的成長率擴大。此外,對個人化醫療的認知不斷增強,以及有利的監管環境的存在,將刺激整個地區對抗體療法的需求。
Antibody therapy market size is projected to expand at 11.8% CAGR from 2023 to 2032. The increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, is fueling the demand for several targeted and personalized treatments.
The increasing advancements in biotechnology and immunology are encouraging the development of novel and more effective antibody therapies. For instance, in September 2023, Manaolana Oncology Inc. was officially launched through a collaboration between The University of Texas MD Anderson Cancer Center and Panacea Venture to develop and advance in antibody-based therapies for targeting the emerging cancer antigens. Additionally, the growing awareness of the benefits of antibody therapy, including reduced side effects and improved treatment outcomes will escalate their demand. The rising investments in R&D activities for antibody-based drugs and the expanding application scope in various medical fields will further drive the market expansion.
The antibody therapy industry is segregated into type, end-use, and region.
The market share from the antibody-drug conjugates segment is estimated to rise at 11.6% CAGR from 2023 to 2032. This is mainly on account of the increasing research and development activities, the rising prevalence of cancer, and the surging advancements in biotechnology. High demand for targeted and personalized therapies will also drive the segment growth.
Antibody therapy market share from the specialty centers end-use segment is projected to rise at 12.5% CAGR between 2023 and 2032. The growth can be attributed to the growing prevalence of chronic diseases, expanding patient pool seeking specialized care, and the rising advancements in precision medicine. Moreover, specialty centers play a crucial role in delivering targeted treatments, driving the adoption of antibody therapies in these centers.
Regionally, the Europe antibody therapy market size is projected to expand at 11.6% growth rate from 2023 and 2032, due to the increasing prevalence of chronic diseases and the rising biopharmaceutical R&D investments. Furthermore, the growing awareness about personalized medicine, and the presence of favorable regulatory environment will fuel the demand for antibody therapies across the region.